Tetracycline
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tetracycline: From Bacterial Infections to Chronic Rhinosinusitis
Note on indication selection: This Evidence Pack contains 10 TxGNN-predicted indications for Tetracycline. The highest-scoring prediction (Punctate Epithelial Keratoconjunctivitis, 99.58%) is supported by only a single case-series-level publication with no clinical trials. Chronic Rhinosinusitis (rank 3, score 99.15%) is presented as the primary candidate in this report because it is the only prediction reaching Evidence Level L2 with actual clinical trial data. The other 9 candidates are summarized in the Appendix for transparency.
One-Sentence Summary
Tetracycline is a broad-spectrum antibiotic of the tetracycline class, historically used for bacterial infections (e.g., acne, respiratory and genitourinary infections, rickettsial disease); detailed original-indication and mechanism-of-action records were not available in this data pull. The TxGNN model predicts potential benefit in Chronic Rhinosinusitis, supported by 4 clinical trials and 20 publications (including a Cochrane systematic review), although nearly all of this evidence was generated with doxycycline — a related tetracycline-class drug — rather than tetracycline itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (tetracycline-class antibiotic); not SAHPRA-registered, so specific approved indication text is unavailable |
| Predicted New Indication | Chronic Rhinosinusitis |
| TxGNN Prediction Score | 99.15% |
| Evidence Level | L2 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Tetracycline is not available in this Evidence Pack (flagged as a High-severity data gap). Based on general pharmacological knowledge, tetracycline is a bacteriostatic agent that inhibits bacterial protein synthesis by binding the 30S ribosomal subunit; drugs in this class (most notably doxycycline) also possess non-antibacterial, anti-inflammatory activity — particularly inhibition of matrix metalloproteinases (MMP-9) and suppression of pro-inflammatory cytokines — even at sub-antimicrobial doses.
Chronic rhinosinusitis (CRS), including CRS with nasal polyps (CRSwNP), is understood to involve both bacterial biofilm colonization and chronic mucosal inflammation with tissue remodeling. The theoretical basis for tetracycline-class therapy in CRS rests on this dual antibacterial/anti-inflammatory mechanism: low-dose, prolonged antibiotic therapy is already used clinically as an adjunct in “difficult-to-treat” CRS, and doxycycline in particular has been studied as an adjunct to systemic steroids for CRSwNP.
The critical caveat is that essentially all of the identified clinical trial and literature evidence involves doxycycline, not tetracycline. While both belong to the same drug class and share the core mechanism, potency, tissue penetration, and anti-inflammatory efficacy are not necessarily interchangeable between individual tetracyclines. This should therefore be regarded as class-level (extrapolated) evidence rather than drug-specific evidence for tetracycline in CRS.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05157412 | Phase 3 | Completed | 60 | Evaluated doxycycline as an adjunct to systemic steroids for CRS with nasal polyps; disease match is exact, but the tested drug is doxycycline, not tetracycline. |
| NCT01198912 | Phase 2 | Completed | 33 | Double-blind, placebo-controlled trial of long-term low-dose oral doxycycline on post-endoscopic sinus surgery wound healing in CRS (with/without polyps); endpoint was wound healing rather than CRS symptom control directly. |
| NCT01825408 | Phase 4 | Completed | 40 | Compared 3 vs. 6 weeks of antibiotic therapy within maximal medical therapy for CRS; good disease match, but the specific tetracycline-class agent used was not confirmed as tetracycline. |
| NCT02569437 | Phase 2 | Terminated | 49 | Investigated doxycycline combined with oral steroids for moderate-to-severe CRSwNP; trial was terminated early (reason not stated), which lowers confidence in this result. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27113482 | 2016 | Systematic Review (Cochrane) | Cochrane Database of Systematic Reviews | Cochrane review of systemic and topical antibiotics as a primary medical management option for chronic rhinosinusitis. |
| 35919933 | 2023 | Systematic Review/Meta-analysis | The Journal of Laryngology & Otology | Systematic review and meta-analysis evaluating the role of doxycycline in the management of chronic rhinosinusitis. |
| 36740870 | 2023 | RCT | American Journal of Rhinology & Allergy | Randomized controlled trial showing doxycycline improves quality of life and anosmia in CRS with nasal polyposis. |
| 32278453 | 2020 | Review | Immunology and Allergy Clinics of North America | Reviews the immunomodulatory role of macrolides and doxycycline (a tetracycline) in recalcitrant CRS, including MMP inhibition. |
| 39937440 | 2025 | Review | Current Opinion in Allergy and Clinical Immunology | Discusses the mechanisms and appropriate clinical use of doxycycline in CRS in the context of newer biologic therapies. |
| 38512383 | 2024 | Systematic Review/Meta-analysis (Comparative) | European Archives of Oto-Rhino-Laryngology | Compares doxycycline against conventional treatments for refractory CRS with nasal polyps. |
| 33877743 | 2021 | Microbiome Cohort Study | International Forum of Allergy & Rhinology | Found sinonasal/gut bacterial composition stable after 1 week of once-daily oral antibiotic treatment for CRS; efficacy of systemic antibiotics for CRS remains uncertain. |
| 15563907 | 2004 | Review | Otolaryngologic Clinics of North America | General review of chronic sinusitis and associated olfactory dysfunction (background/mechanistic context). |
| 9546260 | 1998 | Histology/Basic Science | The Laryngoscope | Histomorphometric study showing ethmoid bone involvement in chronic rhinosinusitis (supports disease pathophysiology, not drug efficacy). |
| 34844745 | 2022 | In Vitro (Biofilm) | Pathology | In vitro study of antibiotic activity, including tetracycline-class agents, against biofilm-forming MRSA/Pseudomonas relevant to CRS pathogens. |
South Africa Market Information
Tetracycline currently has no SAHPRA registration and is not marketed in South Africa (0 registered licenses in the source data). No approved indication text, dosage form, or Essential Medicines List (EML) status could be extracted for the South African market.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(Note: Tetracycline-specific key warnings, contraindications, and drug–drug interaction data were flagged as a Blocking-severity data gap in this Evidence Pack — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The strongest available evidence for tetracycline-class repurposing in Chronic Rhinosinusitis (including a Cochrane systematic review and multiple Phase 2–4 RCTs) is drug-class evidence for doxycycline, not direct evidence for tetracycline; this is class extrapolation, not drug-specific proof of efficacy.
- Tetracycline is not registered with SAHPRA and is not currently marketed in South Africa, so there is no local regulatory or PI basis to evaluate safety or dosing.
- A Blocking-severity data gap exists for TFDA/SAHPRA-equivalent product warnings and contraindications, which must be resolved before any Stage 1 (S1) safety screening can begin.
- A High-severity data gap exists for tetracycline’s mechanism of action, limiting confidence in the mechanistic rationale beyond general drug-class knowledge.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (PI) warnings, precautions, and contraindications for tetracycline (currently a Blocking data gap)
- Confirmed mechanism of action data via DrugBank or equivalent pharmacology reference (currently a High-severity data gap)
- Tetracycline-specific (not doxycycline-only) clinical or pharmacokinetic data supporting anti-inflammatory/anti-MMP activity comparable to doxycycline in sinonasal tissue
- Clarification of whether any of the “Phase 2/3/4” CRS trials used tetracycline itself, to reclassify this from class-extrapolated to drug-specific evidence
- A defined safety monitoring plan, since no drug interaction (DDI) or contraindication data currently exist in this pack
Appendix: Other TxGNN-Predicted Indications Reviewed (Not Selected)
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Recommendation | Why Not Selected |
|---|---|---|---|---|---|
| 1 | Punctate epithelial keratoconjunctivitis | 99.58% | L4 | Hold | Single case-series report describing disease natural history after chlamydial conjunctivitis, not a treatment study; no clinical trials. |
| 2 | Chronic ethmoidal sinusitis | 99.15% | L4 | Hold | Only histology and in-vitro susceptibility data; no clinical trials at this anatomically narrow sub-site. |
| 4 | Paranasal sinus neoplasm | 99.10% | L5 | Hold | Sole supporting reference is an unrelated case report of a surgical ointment complication; likely a knowledge-graph co-occurrence artifact, not a genuine signal. |
| 5 | Exposure keratitis | 98.88% | L5 | Hold | Both supporting references describe unrelated conditions (whirlpool-associated Pseudomonas keratitis; ivermectin/doxycycline for onchocerciasis); no mechanistic relevance to exposure keratitis. |
| 6 | Postinfectious vasculitis | 98.79% | L4 | Hold | Rickettsial disease treatment rationale is plausible, but only a single case report exists, describing disease course rather than treatment outcome. |
| 7 | Post-bacterial disorder | 98.76% | L4 | Hold | Overly broad, non-standard disease label aggregating 50 heterogeneous trials (Lyme disease, Doxy-PEP, resistant infections) with no common endpoint or convergent evidence. |
| 8 | Post-infectious syndrome | 98.71% | L4 | Hold | Similarly broad aggregate label; associated trials span Fragile X syndrome, HIV cognitive impairment, Q fever fatigue, COVID-19, and TB — no coherent indication. |
| 9 | Infective urethral stricture | 98.66% | L4 | Hold | Historical (1970s–80s) literature on gonococcal/nonspecific urethritis; no modern trials evaluating tetracycline for stricture prevention or treatment. |
| 10 | Otitis externa | 98.64% | L3 | Hold | Evidence is almost entirely veterinary (canine/feline) microbiology studies; only one 1959 human clinical study exists, which is outdated and lacks modern trial support. |
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.